文献速递免疫规划慢病防控与筛查

新型靶向药物治疗中多发性骨髓瘤患者肺炎球菌疫苗接种的临床疗效

Clinical efficacy of pneumococcal vaccination in multiple myeloma patients on novel agents: Results of a prospective clinical study.
PubMed 文献 · Vaccine · 2020-05-14

这项前瞻性注册临床试验纳入18例接受新型靶向药物(硼替佐米、来那度胺、伊沙佐米)治疗的多发性骨髓瘤患者,在治疗疗程间给予3剂13价肺炎球菌结合疫苗(PCV13),并与18例匹配对照比较一年观察期内肺炎发生率。结果显示PCV13接种对肺炎发生率有独立影响,绝对风险降低33.3%,需治疗人数为3.0(95%CI 1.61-22.1;P=0.0571),未观察到疫苗不良事件。

要点

  • 多发性骨髓瘤患者接受新型靶向药物期间接种3剂PCV13未见不良事件。
  • PCV13接种使肺炎绝对风险降低33.3%,需治疗人数3.0(95%CI 1.61-22.1;P=0.0571)。
  • 尽管靶向及免疫治疗期间免疫应答可能下降,PCV13仍显示临床有效性。

核心结论

  • 在新型靶向药物治疗的多发性骨髓瘤患者中,于治疗疗程间给予3剂PCV13(间隔至少1个月)具有临床有效性,可降低肺炎发生率。

研究设计与样本

  • 前瞻性注册临床试验(ClinicalTrials.gov NCT03619252),2017至2020年纳入18例接种PCV13的成年多发性骨髓瘤患者及18例匹配对照。
  • PCV13为3剂方案,于新型靶向药物(硼替佐米、来那度胺、伊沙佐米)治疗疗程间接种,间隔至少1个月。
  • 主要结局为一年观察期内肺炎发生率。

主要发现

  • 研究期间未登记到疫苗接种的不良反应。
  • 观察到PCV13接种对肺炎发生率有独立影响。
  • 接种PCV13患者肺炎绝对风险降低33.3%。
  • PCV13接种的需治疗人数为3.0(95%CI 1.61-22.1;P=0.0571)。

关键数值与推荐

  • PCV13接种方案为3剂,每剂间隔至少1个月,于新型靶向药物治疗疗程间给予。
  • 肺炎绝对风险降低33.3%,需治疗人数3.0(95%CI 1.61-22.1;P=0.0571)。

临床怎么用

  • 对接受硼替佐米、来那度胺或伊沙佐米治疗的多发性骨髓瘤患者,可考虑在治疗疗程间接种3剂PCV13(间隔至少1个月)以降低肺炎风险。

局限性

  • 样本量较小(接种组与对照组各18例)。
  • 需治疗人数95%CI较宽(1.61-22.1),P值为0.0571。
  • 观察期仅为一年。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Among the high risk groups, patients with multiple myeloma (MM) have one of the highest incidence of invasive pneumococcal disease, mainly pneumonias. Recent changes in MM treatment have now led to an increase of survival, while the infection-related mortality remains high. The question of efficacy of pneumococcal vaccination in patients receiving novel target agents has not been clinically investigated before. PATIENTS AND METHODS: We have introduced the 3-dose vaccination regimen by 13-valent pneumococcal conjugate (PCV13) vaccine between the treatment courses with novel target agents (bortezomib, lenalidomide, ixazomib) with a minimum of 1 month interval. The incidence of pneumonias during the one-year observation period was taken as a primary outcome in this registered clinical trial. RESULTS: From 2017 to 2020, we have prospectively included 18 adult patients who were vaccinated by PCV13 along with 18 patients of a control matched group. No adverse effects of vaccination were registered in the study. We have observed an independent effect of PCV13 vaccination on the incidence of pneumonias. The absolute risk reduction of pneumonias in patients received PCV13 vaccination was 33.3%. Number needed to treat for PCV13 vaccination in multiple myeloma patients receiving novel agents was 3.0; (95% CI 1.61-22.1; p = 0.0571). CONCLUSION: Therefore, we have shown the clinical effectiveness of PCV13 vaccination schedule based on 3 doses given with a minimum 1 month interval between the courses of novel agents in multiple myeloma patients, despite the expected decrease in immunological response to vaccination during target and immunotherapy. ClinicalTrials.gov Identifier: NCT03619252.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Stoma I, Karpov I, Iskrov I, et al. Clinical efficacy of pneumococcal vaccination in multiple myeloma patients on novel agents: Results of a prospective clinical study. Vaccine. 2020. PMID: 32418789. doi:10.1016/j.vaccine.2020.05.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。